Copyright Reports & Markets. All rights reserved.

Global Drugs for Vulvovaginal Candidiasis Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption 2014-2024
        • 2.1.2 Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region
      • 2.2 Drugs for Vulvovaginal Candidiasis Segment by Type
        • 2.2.1 Cream
        • 2.2.2 Pessary
        • 2.2.3 Other
      • 2.3 Drugs for Vulvovaginal Candidiasis Consumption by Type
        • 2.3.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2014-2019)
      • 2.4 Drugs for Vulvovaginal Candidiasis Segment by Application
        • 2.4.1 Hospital & Clinic
        • 2.4.2 Pharmacy
      • 2.5 Drugs for Vulvovaginal Candidiasis Consumption by Application
        • 2.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Drugs for Vulvovaginal Candidiasis Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2014-2019)

      3 Global Drugs for Vulvovaginal Candidiasis by Players

      • 3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players
        • 3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Players (2017-2019)
        • 3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players (2017-2019)
      • 3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players
        • 3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Players (2017-2019)
        • 3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players (2017-2019)
      • 3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Players
      • 3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Drugs for Vulvovaginal Candidiasis by Regions

      • 4.1 Drugs for Vulvovaginal Candidiasis by Regions
        • 4.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption by Regions
        • 4.1.2 Global Drugs for Vulvovaginal Candidiasis Value by Regions
      • 4.2 Americas Drugs for Vulvovaginal Candidiasis Consumption Growth
      • 4.3 APAC Drugs for Vulvovaginal Candidiasis Consumption Growth
      • 4.4 Europe Drugs for Vulvovaginal Candidiasis Consumption Growth
      • 4.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Growth

      5 Americas

      • 5.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries
        • 5.1.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2014-2019)
        • 5.1.2 Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2014-2019)
      • 5.2 Americas Drugs for Vulvovaginal Candidiasis Consumption by Type
      • 5.3 Americas Drugs for Vulvovaginal Candidiasis Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries
        • 6.1.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2014-2019)
        • 6.1.2 APAC Drugs for Vulvovaginal Candidiasis Value by Countries (2014-2019)
      • 6.2 APAC Drugs for Vulvovaginal Candidiasis Consumption by Type
      • 6.3 APAC Drugs for Vulvovaginal Candidiasis Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries
        • 7.1.1 Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2014-2019)
        • 7.1.2 Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2014-2019)
      • 7.2 Europe Drugs for Vulvovaginal Candidiasis Consumption by Type
      • 7.3 Europe Drugs for Vulvovaginal Candidiasis Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Countries
        • 8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type
      • 8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Drugs for Vulvovaginal Candidiasis Distributors
      • 10.3 Drugs for Vulvovaginal Candidiasis Customer

      11 Global Drugs for Vulvovaginal Candidiasis Market Forecast

      • 11.1 Global Drugs for Vulvovaginal Candidiasis Consumption Forecast (2019-2024)
      • 11.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions
        • 11.2.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions (2019-2024)
        • 11.2.2 Global Drugs for Vulvovaginal Candidiasis Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
      • 11.8 Global Drugs for Vulvovaginal Candidiasis Forecast by Application

      12 Key Players Analysis

      • 12.1 Bayer
        • 12.1.1 Company Details
        • 12.1.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Bayer News
      • 12.2 Perrigo
        • 12.2.1 Company Details
        • 12.2.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Perrigo News
      • 12.3 J & J
        • 12.3.1 Company Details
        • 12.3.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 J & J News
      • 12.4 Pfizer
        • 12.4.1 Company Details
        • 12.4.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Pfizer News
      • 12.5 Bristol-Myers Squibb
        • 12.5.1 Company Details
        • 12.5.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Bristol-Myers Squibb News
      • 12.6 Effik
        • 12.6.1 Company Details
        • 12.6.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Effik News
      • 12.7 Teva
        • 12.7.1 Company Details
        • 12.7.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 Teva News
      • 12.8 Sanofi
        • 12.8.1 Company Details
        • 12.8.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Sanofi News
      • 12.9 Cisen Pharmaceutical
        • 12.9.1 Company Details
        • 12.9.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 Cisen Pharmaceutical News
      • 12.10 Kingyork Group
        • 12.10.1 Company Details
        • 12.10.2 Drugs for Vulvovaginal Candidiasis Product Offered
        • 12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Kingyork Group News

      13 Research Findings and Conclusion

      The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

      Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
      The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
      The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
      Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.

      According to this study, over the next five years the Drugs for Vulvovaginal Candidiasis market will register a 2.1% CAGR in terms of revenue, the global market size will reach US$ 870 million by 2024, from US$ 770 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Vulvovaginal Candidiasis business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions and countries.

      This study considers the Drugs for Vulvovaginal Candidiasis value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Cream
      Pessary
      Other
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Hospital & Clinic
      Pharmacy

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Bayer
      Perrigo
      J & J
      Pfizer
      Bristol-Myers Squibb
      Effik
      Teva
      Sanofi
      Cisen Pharmaceutical
      Kingyork Group

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Drugs for Vulvovaginal Candidiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.
      Focuses on the key global Drugs for Vulvovaginal Candidiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Drugs for Vulvovaginal Candidiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now